In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to ...

French clinical-stage biotechnology and microbiome therapy company MaaT Pharma has seen success with its Phase III trial of MaaT013 meeting its primary endpoints, leading to a jump in the company ...

MaaT Pharma – Investor Relations Guilhaume DEBROAS, Ph.D. Head of Investor Relations +33 6 16 48 92 50 [email protected] MaaT Pharma – Media Relations Pauline RICHAUD Senior PR ...

About MaaT013 MaaT Pharma’s Microbiome Ecosystem Therapies TM (MET) are designed to leverage a full microbiome ecosystem to restore balance and maximize clinical benefits for patients with ...

Ter Maat drove a pickup truck with a 14-foot trailer hitched to the back and stacked with goods. "He's getting phone calls while he's driving down here," Katsma said.

A phase 3 trial of MaaT Pharma’s graft-versus-host disease (GvHD) drug candidate has hit its primary endpoint, positioning the biotech to seek approval of the microbiome therapy in Europe in mid ...

Libertarian Vice Presidential candidate Mike ter Maat says old habits die hard and he expects more interest following the first Presidential debate. Skip Navigation. Share on Facebook; ...

MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to enhancing survival ...